All Pharma News
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
GLOBENEWSWIRE
18 Jul 2024
Share Share
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update
GLOBENEWSWIRE
14 May 2024
Share Share
Immatics Announces Full Year 2023 Financial Results and Corporate Update

Immatics Announces Full Year 2023 Financial Results and Corporate Update
GLOBENEWSWIRE
21 Mar 2024
Share Share
Immatics Announces Proposed Public Offering

Immatics Announces Proposed Public Offering
GLOBENEWSWIRE
17 Jan 2024
Share Share
Immatics Announces Pricing of $175 Million Public Offering

Immatics Announces Pricing of $175 Million Public Offering
GLOBENEWSWIRE
17 Jan 2024
Share Share
Immatics Announces Third Quarter 2023 Financial Results and Business Update

Immatics Announces Third Quarter 2023 Financial Results and Business Update
GLOBENEWSWIRE
14 Nov 2023
Share Share
Immatics Reports Interim Clinical Data from ACTengine® IMA203

Immatics Reports Interim Clinical Data from ACTengine® IMA203
GLOBENEWSWIRE
08 Nov 2023
Share Share
Immatics Receives FDA RMAT Designation for ACTengine® IMA203 TCR-T Monotherapy

Immatics Receives FDA RMAT Designation for ACTengine® IMA203 TCR-T Monotherapy
GLOBENEWSWIRE
24 Oct 2023
Share Share
Moderna, Immatics Ink Potential $1.8B Oncology Deal including Cancer Vaccines

Moderna, Immatics Ink Potential $1.8B Oncology Deal including Cancer Vaccines
BIOSPACE
12 Sep 2023
Share Share
Immatics Announces Second Quarter 2023 Financial Results and Business Update

Immatics Announces Second Quarter 2023 Financial Results and Business Update
GLOBENEWSWIRE
17 Aug 2023
Share Share